Orbimed Advisors LLC C4 Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
A detailed history of Orbimed Advisors LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,830,300 shares of CCCC stock, worth $16.8 Million. This represents 0.35% of its overall portfolio holdings.
Number of Shares
6,830,300
Previous 6,830,300
-0.0%
Holding current value
$16.8 Million
Previous $10.9 Million
10.62%
% of portfolio
0.35%
Previous 0.34%
Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
102Shares Held
57.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$18.3 Million0.06% of portfolio
-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$17.2 Million0.77% of portfolio
-
Morgan Stanley New York, NY4.75MShares$11.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$11.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $120M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...